These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 29801093)

  • 1. Association Between Prescription Drug Monitoring Programs and Nonfatal and Fatal Drug Overdoses: A Systematic Review.
    Fink DS; Schleimer JP; Sarvet A; Grover KK; Delcher C; Castillo-Carniglia A; Kim JH; Rivera-Aguirre AE; Henry SG; Martins SS; Cerdá M
    Ann Intern Med; 2018 Jun; 168(11):783-790. PubMed ID: 29801093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescription drug monitoring programs operational characteristics and fatal heroin poisoning.
    Martins SS; Ponicki W; Smith N; Rivera-Aguirre A; Davis CS; Fink DS; Castillo-Carniglia A; Henry SG; Marshall BDL; Gruenewald P; Cerdá M
    Int J Drug Policy; 2019 Dec; 74():174-180. PubMed ID: 31627159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018.
    Lee B; Zhao W; Yang KC; Ahn YY; Perry BL
    JAMA Netw Open; 2021 Feb; 4(2):e2036687. PubMed ID: 33576816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impacts of prescription drug monitoring program policy changes and county opioid safety coalitions on prescribing and overdose outcomes in California, 2015-2018.
    Henry SG; Shev AB; Crow D; Stewart SL; Wintemute GJ; Fenlon C; Wirtz SJ
    Prev Med; 2021 Dec; 153():106861. PubMed ID: 34687731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State prescription drug monitoring programs and fatal drug overdoses.
    Nam YH; Shea DG; Shi Y; Moran JR
    Am J Manag Care; 2017 May; 23(5):297-303. PubMed ID: 28738683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Provider Prescription Drug Monitoring Program Utilization and Self-Auditing-A Pilot Study.
    Brown WC; Whitted K
    J Dr Nurs Pract; 2020 Jul; 13(2):142-147. PubMed ID: 32817503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10 US States.
    Moyo P; Simoni-Wastila L; Griffin BA; Onukwugha E; Harrington D; Alexander GC; Palumbo F
    Addiction; 2017 Oct; 112(10):1784-1796. PubMed ID: 28498498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effectiveness of prescription drug monitoring programs at reducing opioid-related harms and consequences: a systematic review.
    Rhodes E; Wilson M; Robinson A; Hayden JA; Asbridge M
    BMC Health Serv Res; 2019 Nov; 19(1):784. PubMed ID: 31675963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription drug monitoring programs and drug overdose deaths involving benzodiazepines and prescription opioids.
    Liang D; Shi Y
    Drug Alcohol Rev; 2019 Jul; 38(5):494-502. PubMed ID: 31317593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring Relationships Between Proactive Reporting State-level Prescription Drug Monitoring Programs and County-level Fatal Prescription Opioid Overdoses.
    Cerdá M; Ponicki WR; Smith N; Rivera-Aguirre A; Davis CS; Marshall BDL; Fink DS; Henry SG; Castillo-Carniglia A; Wintemute GJ; Gaidus A; Gruenewald PJ; Martins SS
    Epidemiology; 2020 Jan; 31(1):32-42. PubMed ID: 31596794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between State Laws Facilitating Pharmacy Distribution of Naloxone and Risk of Fatal Overdose.
    Abouk R; Pacula RL; Powell D
    JAMA Intern Med; 2019 Jun; 179(6):805-811. PubMed ID: 31058922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Prescription Drug Monitoring Programs With Opioid Prescribing and Overdose in Adolescents and Young Adults.
    Toce MS; Michelson KA; Hudgins JD; Hadland SE; Olson KL; Monuteaux MC; Bourgeois FT
    Ann Emerg Med; 2023 Apr; 81(4):429-437. PubMed ID: 36669914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription drug monitoring programs, nonmedical use of prescription drugs, and heroin use: Evidence from the National Survey of Drug Use and Health.
    Ali MM; Dowd WN; Classen T; Mutter R; Novak SP
    Addict Behav; 2017 Jun; 69():65-77. PubMed ID: 28152391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of prescription drug monitoring and medical cannabis legislation on opioid overdose mortality.
    Phillips E; Gazmararian J
    J Opioid Manag; 2017; 13(4):229-239. PubMed ID: 28953315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A typology of prescription drug monitoring programs: a latent transition analysis of the evolution of programs from 1999 to 2016.
    Smith N; Martins SS; Kim J; Rivera-Aguirre A; Fink DS; Castillo-Carniglia A; Henry SG; Mooney SJ; Marshall BDL; Davis C; Cerdá M
    Addiction; 2019 Feb; 114(2):248-258. PubMed ID: 30207015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in opioid and other analgesic prescribing following voluntary and mandatory prescription drug monitoring program implementation: A time series analysis of early outcomes.
    Nielsen S; Picco L; Russell G; Pearce C; Andrew NE; Lubman DI; Bell JS; Buchbinder R; Xia T
    Int J Drug Policy; 2023 Jul; 117():104053. PubMed ID: 37209441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription drug monitoring program design and function: A qualitative analysis.
    Rutkow L; Smith KC; Lai AY; Vernick JS; Davis CS; Alexander GC
    Drug Alcohol Depend; 2017 Nov; 180():395-400. PubMed ID: 28978492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. State-level prescription drug monitoring program mandates and adolescent injection drug use in the United States, 1995-2017: A difference-in-differences analysis.
    Earlywine JJ; Hadland SE; Raifman J
    PLoS Med; 2020 Sep; 17(9):e1003272. PubMed ID: 32976539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription drug monitoring programs evaluation: A systematic review of reviews.
    Tay E; Makeham M; Laba TL; Baysari M
    Drug Alcohol Depend; 2023 Jun; 247():109887. PubMed ID: 37126936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.